Skip to content
Stock screener

PACB Pacific Biosciences of California, Inc. stock chart & analysis

Conviction 36IndustrialsScan · Thu, Nov 19, 2026

Pacific Biosciences of California, Inc. (PACB) closed at $1.76 (-4.10%) on Nov 19, 2026. Price is below its 50-day and above its 200-day moving average. RSI(14) 38, RS Rating 90, -48.9% from its 52-week high, -6.2% year to date. Sector: Industrials · Laboratory Analytical Instruments.

PACB$1.76-4.10%
ResistanceSupportVol 14Insider sell
Loading chart…

Why PACB moved

From the StockSetups movers recaps that covered PACB, newest first. A recap states what was known that day.

  • Close+29.5%

    No news headlines are on file for PACB on September 30. The catalyst is unclear. However, given the stock's massive short interest of 49.6 million shares and 6.8 days to cover, a short squeeze is a very plausible explanation.

    Top Stock Movers Sept 30, 2026: TGE, CMCT, PACB →
Pacific Biosciences of California, Inc.Laboratory Analytical Instrumentswww.pacb.com ↗
Price1.76
Change-4.10%
Gap+1.64%
Rel volume1.26×
Avg volume13.48M
Avg $ vol31.14M
SMA 202.25
SMA 502.05
SMA 2001.60
Price vs 50-14.19%
Price vs 200+9.97%
MA stackmixed
50/200 cross—
Supertrenddown · 2.56
RSI (14)38
MACD hist-0.09
MACD cross—
Stoch %K / %D4 / 7
ADX (14)23
+DI / −DI19 / 25
RSI divergenceBearish
MACD divergenceBearish
ATR %14.39%
ADR %11.67%
52w high3.44
52w low1.07
From 52w high-48.91%
Above 52w low+64.02%
New 52w highNo
SqueezeOff
Bollinger width57.39%
%B0.12
Donchian pos3.32%
Donchian high3.07
Donchian low1.71
AVWAP (52w high)2.32
vs AVWAP high-24.48%
AVWAP (52w low)2.08
vs AVWAP low-15.79%
OBV trendFlat
Chaikin MF (20)-0.09
Today vs 20d1.26×
Avg vol (14d)12.49M
Avg vol (20d)13.48M
Avg $ vol (20d)31.14M
Market cap549.19M
RS Rating90 / 99
RS 3m (vs SPY)+36.51%
RS 6m (vs SPY)+44.02%
RS line new highNo
Trend template5/8
Technical rank67.7
1 week-10.91%
1 month-17.99%
3 months+30.00%
6 months+40.40%
1 year+6.36%
YTD-6.15%
P/E-1.01
P/B-8.95
P/S—
P/FCF-4.82
EPS-1.82
Div yield—
ROE890.15%
ROA-75.77%
Debt/Eq-14.61
Current4.62
EV/EBITDA—
Gross margin—
Net margin—
Rev growth-15.88%
EPS growth-76.34%
Price target2.64
Target upside50.43%
Analyst ratingBuy
Institutional74.17%
Ent. value1.39B
Revenue40.56M
Net income-37.85M
Gross profit13.47M
Free cash flow-113.92M
IndustryLaboratory Analytical Instruments
ExchangeNasdaq
Shares out—
Employees485
ListedWed, Oct 27, 2010
Free float259.69M
Float %86.0%
Short interest—
Days to cover—
Short volume63.9%
Squeeze score—
Next earnings—
EPS forecast—
Last EPS vs est−$0.11 vs −$0.13
Last surprise+15.4% beat
Setup gradeD
Conviction36 / 100
Pattern quality—
Tech rank67.7 / 100
Group rank41 / 100
Status laneNo active setup
Setup direction—
Pattern family
Resistance3.25
Support1.75
Days since event—
Candle confirm—

Financials as of Wed, Sep 30, 2026 · quarterly.

PACB technical analysis

Trend

PACB's moving averages are mixed — no clean uptrend or downtrend. It closed 14.2% below the 50-day ($2.05) and 10.0% above the 200-day ($1.60). ADX(14) at 23 points to a moderate trend. It meets 5 of 8 trend-template criteria.

Momentum

RSI(14) is 38, in the bearish half of its range. The MACD histogram is negative. A bearish RSI divergence is in place. A bearish MACD divergence is in place. Its RS Rating of 90 puts its weighted 12-month performance ahead of about 90% of the US market.

Volume and volatility

Volume on the latest session ran 1.3× its 20-day average. It trades about $31.1M a day on average. ATR(14) is $0.2525, 14.4% of price — its typical daily range. Chaikin Money Flow (-0.09) shows distribution.

Key levels

The chart pattern's support is $1.75 and its resistance $3.25. The 52-week range is $1.07 to $3.44; price is 48.9% below the high and 64.0% above the low. The VWAP anchored at the 52-week high is $2.32, above price.

Performance

PACB returned -10.9% (1 week), -18.0% (1 month), +30.0% (3 months), +40.4% (6 months), +6.4% (1 year), -6.2% (year to date).

About Pacific Biosciences of California, Inc.

Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Europe Middle East, and Africa and Asia-Pacific.

Laboratory Analytical Instruments · Listed 2010 · 485 employees

Insider activity

SEC Form 4 transactions in PACB · open-market 1 sell

InsiderSideShares
Van Oene Mark
See Remarks · Common Stock · 2026-08-17
Sell26.91K
Van Oene Mark
See Remarks · Common Stock · 2026-08-10
Grant489.13K
Van Oene Mark
See Remarks · Stock Option (right to buy) · 2026-08-10
Grant1.97M
Ericson William W.
Director · Stock Option (right to buy) · 2026-06-03
Grant223.49K
LIVINGSTON RANDALL S
Director · Stock Option (right to buy) · 2026-06-03
Grant223.49K
Smith Christopher M
Director · Stock Option (right to buy) · 2026-06-03
Grant223.49K
MOHR MARSHALL
Director · Stock Option (right to buy) · 2026-06-03
Grant223.49K
Gibson Christopher
Director · Stock Option (right to buy) · 2026-06-03
Grant74.5K
ORDONEZ KATHY
Director · Stock Option (right to buy) · 2026-06-03
Grant223.49K
MILLIGAN JOHN F
Director · Stock Option (right to buy) · 2026-06-03
Grant223.49K

SEC filings

EDGAR filings in PACB · 10 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, no credit card.

Start free — 7-day trial, no card →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.